On November 27, Gelonghui reported that zhejiang hisoar pharmaceutical (002099.SZ) recently stated in an investor relations activity that the company is maintaining a "production-end advantage + BD-end expansion" dual-driver development in the CMO/CDMO business. There is a good growth momentum for existing products with strategic cooperative customers, and the pace of new project integration is continuously accelerating. The non-sterile active pharmaceutical ingredient project for the Peinan original research client has completed the verification batch delivery, and the company is assisting the client with global market certification; additionally, other anti-infection projects are in the verification batch stage.